Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kan He

Showing results (171-180 of 188) with videos related to

Pageof 19
Sort By:
Biomaterials|February 23, 2021
Biomimetic co-assembled nanodrug of doxorubicin and berberine suppresses chemotherapy-exacerbated breast cancer metastasisXiao Zheng, Yawei Zhao, Yong Jia, et al.
Acta Biomaterialia|September 30, 2019
Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrenceFan Zhang, Yong Jia, Xiao Zheng, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitorsJeffrey G Varnes, Dean A Wacker, Donald J P Pinto, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2007
Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitorsJeffrey G Varnes, Dean A Wacker, Irina C Jacobson, et al.
Bioorganic & Medicinal Chemistry Letters|December 19, 2006
Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residuesJennifer X Qiao, Xuhong Cheng, Joanne M Smallheer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2008
Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeysLisa J Christopher, Donghui Cui, Wenying Li, et al.
Journal of Medicinal Chemistry|October 5, 2007
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Stephanie Koch, et al.
Iscience|April 18, 2025
CT-based artificial intelligence system complementing deep learning model and radiologist for liver fibrosis stagingShuang Zheng, Wenao Ma, Lin Mu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2008
Metabolism and disposition of dasatinib after oral administration to humansLisa J Christopher, Donghui Cui, Chiyuan Wu, et al.
Molecular Systems Biology|June 12, 2015
Systems-level quantification of division timing reveals a common genetic architecture controlling asynchrony and fate asymmetryVincy Wing Sze Ho, Ming-Kin Wong, Xiaomeng An, et al.
Pageof 19

Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
Biomaterials|February 23, 2021
Biomimetic co-assembled nanodrug of doxorubicin and berberine suppresses chemotherapy-exacerbated breast cancer metastasisXiao Zheng, Yawei Zhao, Yong Jia, et al.
Acta Biomaterialia|September 30, 2019
Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrenceFan Zhang, Yong Jia, Xiao Zheng, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitorsJeffrey G Varnes, Dean A Wacker, Donald J P Pinto, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2007
Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitorsJeffrey G Varnes, Dean A Wacker, Irina C Jacobson, et al.
Bioorganic & Medicinal Chemistry Letters|December 19, 2006
Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residuesJennifer X Qiao, Xuhong Cheng, Joanne M Smallheer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2008
Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeysLisa J Christopher, Donghui Cui, Wenying Li, et al.
Journal of Medicinal Chemistry|October 5, 2007
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Stephanie Koch, et al.
Iscience|April 18, 2025
CT-based artificial intelligence system complementing deep learning model and radiologist for liver fibrosis stagingShuang Zheng, Wenao Ma, Lin Mu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2008
Metabolism and disposition of dasatinib after oral administration to humansLisa J Christopher, Donghui Cui, Chiyuan Wu, et al.
Molecular Systems Biology|June 12, 2015
Systems-level quantification of division timing reveals a common genetic architecture controlling asynchrony and fate asymmetryVincy Wing Sze Ho, Ming-Kin Wong, Xiaomeng An, et al.
Pageof 19